Unlike colon carcinoma, where tumors harboring mutant KRAS are known to be resistant to EGFR inhibition [33], the significance of KRAS mutations upon the benefit of anti-EGFR therapies in patients with lung cancer remains unclear [34]. Here, KRAS is linked to lung carcinoma.